Ron Bose

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 84%
3. Mutation 60%
4. Trastuzumab 57%
5. Phosphotransferases 32%
6. Protein-Tyrosine Kinases 26%
7. Circulating Tumor DNA 25%
8. Neoplasms 23%
9. ErbB Receptors 23%
10. pertuzumab 23%
11. Ado-Trastuzumab Emtansine 21%
12. Genome 18%
13. zirconium-89-trastuzumab 17%
14. human ERBB2 protein 16%
15. Paclitaxel 16%
16. Therapeutics 15%
17. Ceramides 14%
18. Genes 14%
19. Estrogen Receptors 12%
20. Phosphorylation 12%
21. Capecitabine 12%
22. Lapatinib 11%
23. Fulvestrant 11%
24. Clinical Trials 11%
25. erbB-2 Genes 10%
26. Receptor Protein-Tyrosine Kinases 10%
27. Loperamide 10%
28. Diarrhea 10%
29. Proteins 10%
30. Randomized Controlled Trials 8%
31. Progression-Free Survival 8%
32. palbociclib 8%
33. DNA Sequence Analysis 7%
34. Proteomics 7%
35. Gene Amplification 7%
36. Confidence Intervals 7%
37. Tyrosine 7%
38. TEV protease 7%
39. Colorectal Neoplasms 7%
40. Phosphopeptides 6%
41. Phosphotyrosine 6%
42. Psychological Inhibition 6%
43. Dimerization 6%
44. dihydroceramide desaturase 6%
45. Squamous Cell Neoplasms 6%
46. Apoptosis 6%
47. Lobular Carcinoma 6%
48. CSK Tyrosine-Protein Kinase 6%
49. Drug Resistance 6%
50. Safety 6%